Genomic Biomarker for Prostate Cancer Focal Therapy: Post Hoc Assessment of a Phase II Clinical Trial
Adam B. Weiner(Cedars-Sinai Medical Center), Leonard S. Marks(Urological Research Foundation), Wayne Brisbane(University of California, Los Angeles), Mamdouh Aker(University of California, Los Angeles), Michelle Cardenas(University of California, Los Angeles), James A. Proudfoot(Veracyte (United States)), Eileen M. Kelly(Veracyte (United States)), Elai Davicioni(Coherus BioSciences (United States)), Samantha Gonzalez(University of California, Los Angeles), Anthony Sisk(University of California, Los Angeles)
Cited by 3
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798
An overview of kidney stone imaging techniques
|Nature Reviews Urology|2016|389
Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging
|Cancer Research|2014|264
Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling
|European Urology|2022|169
Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
|Clinical Cancer Research|2018|126